This article is more than 5 years old. Information may no longer be current.

Potentia Pharmaceuticals licenses anti-AMD peptides from the University of Pennsylvania

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

LOUISVILLE, Ky. — Potentia Pharmaceuticals Inc. has entered into an exclusive licensing agreement with the University of Pennsylvania to develop a new drug for age-related macular degeneration, the company announced.

The agreement allows Potentia to begin preclinical development of a drug based on the university's compstatin class of complement-inhibiting peptides. Compstatin inhibits complement activation, an inflammatory immune response that may lead to tissue damage. Recent studies have linked genes encoding the complement system to a predisposition toward AMD, the company said.

Potentia will evaluate the drug for treating both wet and dry AMD. Company officials expect to begin a phase 1 clinical trial in the first half of 2007, according to the release.